249 related articles for article (PubMed ID: 9617508)
21. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
Lyons KE; Pahwa R
Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
[TBL] [Abstract][Full Text] [Related]
22. Ropinirole: a review of its use in the management of Parkinson's disease.
Matheson AJ; Spencer CM
Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
[TBL] [Abstract][Full Text] [Related]
23. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
24. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
Pahwa R; Stacy MA; Factor SA; Lyons KE; Stocchi F; Hersh BP; Elmer LW; Truong DD; Earl NL;
Neurology; 2007 Apr; 68(14):1108-15. PubMed ID: 17404192
[TBL] [Abstract][Full Text] [Related]
25. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
26. Ropinirole: new indication. Restless legs: disproportionate adverse effects.
Prescrire Int; 2006 Oct; 15(85):173-6. PubMed ID: 17128523
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
Tompson D; Oliver-Willwong R
Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
[TBL] [Abstract][Full Text] [Related]
28. An evaluation of bromocriptine in the treatment of Parkinson's disease.
Mackenzie RA; Lance JW
Clin Exp Neurol; 1978; 15():228-36. PubMed ID: 386307
[TBL] [Abstract][Full Text] [Related]
29. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
[TBL] [Abstract][Full Text] [Related]
30. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; (1):CD001517. PubMed ID: 11279719
[TBL] [Abstract][Full Text] [Related]
31. Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease.
Makumi CW; Asgharian A; Ellis J; Shaikh S; Jimenez T; VanMeter S
Int J Neurosci; 2016; 126(1):30-8. PubMed ID: 25495896
[TBL] [Abstract][Full Text] [Related]
32. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
33. Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease.
Hauser RA; Reichmann H; Lew M; Asgharian A; Makumi C; Shulman KJ
Int J Neurosci; 2011 May; 121(5):246-53. PubMed ID: 21244307
[TBL] [Abstract][Full Text] [Related]
34. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2000; 2001(3):CD001517. PubMed ID: 10908504
[TBL] [Abstract][Full Text] [Related]
35. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
[No Abstract] [Full Text] [Related]
36. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.
Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE; Abdalla M;
Mov Disord; 2006 Nov; 21(11):1844-50. PubMed ID: 16958094
[TBL] [Abstract][Full Text] [Related]
37. Pergolide and Parkinson's disease: new preparation. No clear benefit.
Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
[TBL] [Abstract][Full Text] [Related]
38. Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and safety of ropinirole in the treatment of Parkinson's disease: a multi-center, randomized, double-blind and bromocriptine-controlled trial].
Li SH; Chen HB; Wang ZF; Tang RH; Zhang XY; Yang JS; Zhao WQ; Sun XR; Ma J
Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(25):1952-7. PubMed ID: 24169242
[TBL] [Abstract][Full Text] [Related]
40. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.
Montplaisir J; Karrasch J; Haan J; Volc D
Mov Disord; 2006 Oct; 21(10):1627-35. PubMed ID: 16874755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
